Compare Cassava Sciences Inc (FLNA) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

WMS trades at $151.04, up 2.32% today, with a bullish technical signal from moving averages. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. Revenue for 2025 was $2.90B, with a net income margin of 13.98%. Recent news includes a dividend increase and a scheduled Investor Day.

The outlook is supported by strong profitability and a consensus price target of $184.43, implying 22% upside. Risks include a recent Zacks Strong Sell rating and projected earnings decline in 2026. Investor sentiment is mixed, with 41% of analysts rating Buy but some institutional selling noted.